Compare Organon & Co. Common Stock (OGN) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Public Storage — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Public Storage trades at $290.77 (market cap $53.89B). The key difference: Public Storage is far larger — about 14.9× Organon & Co. Common Stock's market cap, and Public Storage pays the higher dividend (4.16%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Public Storage for 130 Days on average.
| OGN | PSA | |
|---|---|---|
Market Cap | $3.62B | $53.89B |
Volume | 2,892,999 | 947,047 |
Sector | Health | Real Estate |
52-Week High | $13.81 | $330.47 |
52-Week Low | $5.70 | $258.44 |
Typical Hold Time | 0 Days | 130 Days |
Enterprise Value | $11.04B | $68.16B |
Dividend Yield | 0.58% | 4.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Public Storage (PSA) trades at $288.76, showing minimal daily movement (-0.04%) with neutral technical indicators. The REIT maintains strong fundamentals including a 41.8% net income margin and consistent earnings beats, though valuation metrics appear elevated with a P/E of 27.52. Recent developments include the completion of the Public Storage Canada acquisition and a $400 million Canadian debt offering, positioning for strategic growth.
PSA presents a mixed outlook with analyst consensus pointing to 14% upside to the $328.33 price target, though the majority (64%) recommend Hold. Key risks include REIT sector sensitivity to interest rates and competitive pressures, while the 4.05% dividend yield provides income stability. The stock's premium valuation requires sustained operational execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
